The UK Court held that three of Cephalon’s patents relating to the drug modafinil, used to treat sleep disorders such as narcolepsy, were not infringed and were invalid for lack of inventive step. Click here for the full text of this case. A full summary of this case has been published on Kluwer IP Law.
The Court of Appeal discusses and builds on its previous case law on patentability regarding the issue of whether the subject matter is considered a technical invention. The Court emphasizes that it is sufficient if only part of the patented teaching concerns a technical problem. However, as the next step it has to be determined…
The Antwerp Court of Appeal dismissed the claims of the Spanish pharmaceutical company Almirall against Teva Pharma Belgium (Teva) relating to the generic ebastin. It confirmed the decision of the President of the Antwerp Commercial Court, although the Court of Appeal based its decision on other grounds. As discussed in a previous post, Almirall started…
by Stephan von Petersdorff-Campen In my post of 28 April 2011, I reported that the Düsseldorf Appellate Court (Oberlan-desgericht) does not require urgency for inspection orders, whereas urgency is re-quired for preliminary cease and desist orders. Urgency means that the patentee is compelled to apply for an interim injunction in due time (approx. 1 month)…
To stay, or not to stay, that is the question. But not in the recent Danisco v. Novozymes case before the District Court of The Hague. On the face of the Court’s decision of 22 June 2011, the question whether to stay the national proceedings pending the outcome of opposition proceedings at the EPO on…
After years of not having handed down judgments in patent cases, in recent months the Supreme Court has handed down several interesting judgments which will hopefully give more guidance to lower level Courts. The last judgment in this recent saga, handed down on 18 July 2011, has confirmed the judgment of 19 December 2006 from…
In this blog, we reported earlier about a new nullity action initiated in 2010 against the German supplementary protection certificate (SPC) for enantiomeric escitalopram and the judgment of the German Federal Patent Court (Bundespatentgericht – BPatG) in favor of the validity of the SPC. Meanwhile, the BPatG issued the written grounds for its decision.
A method claim comprising a step of “providing a donor flow channel for conveying fluid to and from a donor” was found to be excluded from patentability as treatment by surgery and therapy. The Board derived from the description that this step required performing venipuncture and found that venipuncture required professional medical expertise to be…
This blog relates to the decision “Lungenfunktionsmessgerät” (lung function analyser) by the Higher Regional Court (Oberlandesgericht) of Duesseldorf (judgement of 24 February 2011, docket no. I-2 U 122/09). The court had to deal with the differentiation between direct and indirect patent infringement. The patent in suit, EP 0 606 351, provided for an apparatus for…
Since 2009, French law has allowed patentees to voluntarily limit their granted patent claims. This possibility, which has existed for a long time in a number of European countries, (e.g. Austria, Switzerland, Germany, Denmark, Italy, Norway and the United Kingdom) has recently been introduced into the European patent system through Art. 105bis et seq. of the…
